ENYO PHARMA ANNOUNCES MULTIPLE EYP001 DATA PRESENTATIONS AT AASLD CONFERENCE
Lyon, France. October 17, 2019 – ENYO Pharma will be present at the AASLD in Boston in November to present four Posters and one Oral presentation For its Lead Compound EYP001. ENYO will also hold KOL Symposium to Provide Scientific Update on Potential Benefits of FXR Agonists for HBV treatment, on the 10th of November.
ENYO PHARMA ANNOUNCES MOVE TO NEW CORPORATE HEADQUARTERS
Lyon, France., October 3rd, 2019 – ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, today announced the relocation of the Company’s headquarters to the 8th Arrondissement in Lyon in the BIOSERRA buildings at 60 avenue Rockefeller, to support long-term growth and advancement of pipeline.
AASLD
8-12 November, 2019
Boston, Massachusetts
ENYO Pharma attended the AASLD meeting in Boston and presented four posters as well as performed an oral presentation around FXR agonists in HBV and NASH.
During the conference, ENYO Pharma sponsored a Symposium to discuss recent advances in the understanding of the replication of Hepatitis B (HBV) and the potential ability of Farnesoid X receptor (FXR) agonists, such as EYP001, to provide a functional cure for HBV.
Collaboration with the Swiss Institute of Bioinformatics
ENYO Pharma is pleased to announce the initiation of a bioinformatics collaboration with Lydie Lane and Amos Bairoch of the CALIPHO group, part of the SIB Swiss Institute of Bioinformatics and the University of Geneva. The CALIPHO group aims at using a combination of bioinformatics and experimental methodologies to increase the knowledge on human proteins. Together, we will integrate ENYO’s unique protein interactome datasets within neXtProt, a comprehensive human-centric discovery platform,
Targeting Immunometabolism in Autoimmune Diseases and Inflammation conference
22 October, 2019
New-York, USA
ENYO Pharma will participate to the “Targeting Immunometabolism in Autoimmune diseases and Inflamamtion conference” in New York and will present a poste entitled “A novel small molecule modulating mitochondrial activity improves inflammation in a diet-induced NASH model”
Latest Press Release 